Parkinson's - MJFF launches series of funding programmes ($ 1,000,000)

The Michael J. Fox Foundation (MJFF) has launched a new series of funding programmes:
• MJFF Biosample and Tissue Resource RFA - Fall 2013: Pre-proposals due: April 3, 2013, up to $ 500,000;
• LRRK2 Pharmacodynamic Assays 2013: Pre-proposals due: April 3, 2013, up to two years and $ 250,000 in total costs;
• Target Validation - Fall 2013: Pre-proposals Due: May 29, 2013, up to $ 250,000;
• Therapeutic Pipeline Program - Fall 2013: Pre-proposals due: April 3, 2013, differs per project;
• Synuclein Therapeutic Acceleration Program (SynTAP 2013): Pre-proposals due: April 3, 2013, up to two years and a maximum of $ 1,000,000 in total costs.

Other upcoming funding opportunities are:
• Rapid Response Innovation Awards: No deadline; Applications accepted anytime, up to $ 75,000;
• Dyskinesia Challenge 2013: No deadline; applications accepted anytime up to one year in duration and $ 125,000;
• LRRK2 Challenge 2013: No deadline; applications accepted anytime, up to one year and $ 125,000;
• Neurotrophic Factors Challenge 2013: No deadline; applications accepted anytime, up to one year in duration and $ 125,000.

The Michael J. Fox Foundation works tirelessly to accelerate promising research toward clinical testing and breakthroughs for Parkinson’s patients. While our strong emphasis is on funding translational and clinical research, we also support high-risk/high-reward discovery work to help keep new ideas flowing into the drug development pipeline.